Quanterix (NASDAQ:QTRX – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04), FiscalAI reports. The firm had revenue of $34.97 million during the quarter, compared to the consensus estimate of $33.85 million. Quanterix had a negative return on equity of 29.02% and a negative net margin of 75.05%.
Here are the key takeaways from Quanterix’s conference call:
- Q3 revenue was $35 million, up 6.3% sequentially but down 13.1% year over year (8.6% on a pro forma basis). Quanterix narrowed its 2026 revenue outlook to $142 million–$146 million and expects a stronger Q4, while noting the commercial changes will have a larger impact in 2027.
- Spatial revenue grew by a double-digit percentage sequentially, with consumables reaching their second-highest level ever. Accelerator Lab bookings improved for a second consecutive quarter, with book-to-bill approaching 2x.
- LucentAD Complete test volume more than doubled sequentially, and new lab partnerships are expected to expand its reach. Florida Medicaid coverage took effect at a reimbursement rate of $484 per test for eligible residents, though diagnostic revenue remains relatively small and FDA timing is uncertain.
- Cash usage was $16.2 million in Q3, leaving $80.7 million on hand; the company expects to end 2026 with about $70 million and no debt. Management reiterated its cash-flow breakeven target for 2027, after moving that goal out from 2026.
Quanterix Price Performance
NASDAQ QTRX traded down $0.05 during trading hours on Wednesday, reaching $3.23. 214,402 shares of the stock traded hands, compared to its average volume of 855,989. The stock has a 50 day simple moving average of $3.03 and a two-hundred day simple moving average of $3.76. Quanterix has a 1 year low of $2.15 and a 1 year high of $8.77. The company has a market cap of $152.76 million, a price-to-earnings ratio of -1.37 and a beta of 1.06.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on QTRX. Weiss Ratings restated a “sell (e+)” rating on shares of Quanterix in a research note on Wednesday, November 4th. Canaccord Genuity Group dropped their price target on Quanterix from $4.00 to $3.00 and set a “hold” rating for the company in a research report on Monday, August 17th. TD Cowen boosted their price objective on Quanterix from $3.50 to $4.00 and gave the stock a “hold” rating in a report on Tuesday. Finally, Wall Street Zen cut shares of Quanterix from a “hold” rating to a “sell” rating in a research report on Saturday. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $3.50.
Get Our Latest Stock Report on Quanterix
About Quanterix
Quanterix Corporation (NASDAQ:QTRX) is a life sciences company that develops ultra-sensitive digital immunoassay technologies for detecting and measuring biomarkers in blood and other biological samples. Its platform is designed to identify proteins and other molecules at very low concentrations, supporting research into disease biology, diagnosis, treatment response and drug development. The company’s principal technology, Simoa, uses digital detection methods to improve the sensitivity of immunoassays.
Read More
- Five stocks we like better than Quanterix
- Can Constellation Energy’s Contracts Power a Stock Rebound?
- Why Apple Stock Looks Like a Safe Haven After the Midterms
- IonQ Raised the Bar, But 3 Quantum Rivals Face Tough Questions
- On Holding’s Sell-Off Overlooks a Key Part of Its Earnings Story
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.
